Skip to main content

Protein biomarker for the prediction of response to endocrine treatment in breast cancer patients

Objective

Classical pathologic parameters have been used to inform adjuvant clinical treatment choices for early breast cancer patients. There remain a significant number of patients however, who despite a reportedly favourable prognostic profile, experience metastatic disease. Elucidation of the mechanisms of tumour adaptability and the identification of predictive markers of early recurrence is the basis of personalized medicine. Work from our group has established the developmental protein HOXC11 as a powerful predictor of resistance to endocrine treatment in breast cancer patients .The aim of this project is to establish a joint industry-academia partnership to produce a commercially viable and clinically validated predictive assay/kit which based on the use of HOXC11 as a predictive biomarker of poor response to endocrine treatment in breast cancer patients.

Call for proposal

FP7-PEOPLE-2012-IAPP
See other projects for this call

Coordinator

ROYAL COLLEGE OF SURGEONS IN IRELAND
Address
Saint Stephen's Green 123
2 Dublin
Ireland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 390 695,04
Administrative Contact
Leonie Young (Prof.)

Participants (1)

ALMAC DIAGNOSTIC SERVICES LIMITED
United Kingdom
EU contribution
€ 179 618,56
Address
Seagoe Industrial Estate 20
BT63 5QD Craigavon
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Karen Keating (Dr.)